-
Je něco špatně v tomto záznamu ?
Synthesis, characterization and in vitro evaluation of substituted N-(2-phenylcyclopropyl)carbamates as acetyl- and butyrylcholinesterase inhibitors
E. Horáková, P. Drabina, B. Brož, Š. Štěpánková, K. Vorčáková, K. Královec, R. Havelek, M. Sedlák,
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články
NLK
Taylor & Francis Open Access
od 2002-01-01
Medline Complete (EBSCOhost)
od 2007-02-01
- MeSH
- acetylcholinesterasa metabolismus MeSH
- butyrylcholinesterasa metabolismus MeSH
- cholinesterasové inhibitory chemická syntéza chemie farmakologie MeSH
- Jurkat buňky MeSH
- karbamáty chemická syntéza chemie farmakologie MeSH
- lidé MeSH
- molekulární struktura MeSH
- viabilita buněk účinky léků MeSH
- vztah mezi dávkou a účinkem léčiva MeSH
- vztahy mezi strukturou a aktivitou MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
A serie of O-substituted N-2-phenylcyclopropylcarbamates was prepared and characterized. These carbamates were tested as inhibitors of acetylcholinesterase (AChE) and butyrylcholinesterase (BChE). It was found, that these compounds exhibit moderate inhibition activity with values of IC50 in the range of 54.8-94.4 μM (for AChE) and up to 5.8 μM (for BChE). The AChE/BChE selectivity for each carbamate was calculated. These values varied from 0.50 to 9.46, two carbamate derivatives inhibited only AChE selectively. The most promising derivative was prepared in all optically pure forms (four isomers). It was found that individual stereoisomers differed only slightly in the inhibition ability. The cytotoxicity of all carbamates was evaluated using the standard in vitro test with Jurkat cells. With regard to their inhibition activity and cytotoxicity as well as easy preparation, O-substituted N-2-phenylcyclopropylcarbamates can be considered as promising compounds for potential medicinal applications.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc17013610
- 003
- CZ-PrNML
- 005
- 20170502094259.0
- 007
- ta
- 008
- 170413s2016 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1080/14756366.2016.1212193 $2 doi
- 035 __
- $a (PubMed)27476673
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Horáková, Eva $u a Institute of Organic Chemistry and Technology, Faculty of Chemical Technology, University of Pardubice , Pardubice , Czech Republic and.
- 245 10
- $a Synthesis, characterization and in vitro evaluation of substituted N-(2-phenylcyclopropyl)carbamates as acetyl- and butyrylcholinesterase inhibitors / $c E. Horáková, P. Drabina, B. Brož, Š. Štěpánková, K. Vorčáková, K. Královec, R. Havelek, M. Sedlák,
- 520 9_
- $a A serie of O-substituted N-2-phenylcyclopropylcarbamates was prepared and characterized. These carbamates were tested as inhibitors of acetylcholinesterase (AChE) and butyrylcholinesterase (BChE). It was found, that these compounds exhibit moderate inhibition activity with values of IC50 in the range of 54.8-94.4 μM (for AChE) and up to 5.8 μM (for BChE). The AChE/BChE selectivity for each carbamate was calculated. These values varied from 0.50 to 9.46, two carbamate derivatives inhibited only AChE selectively. The most promising derivative was prepared in all optically pure forms (four isomers). It was found that individual stereoisomers differed only slightly in the inhibition ability. The cytotoxicity of all carbamates was evaluated using the standard in vitro test with Jurkat cells. With regard to their inhibition activity and cytotoxicity as well as easy preparation, O-substituted N-2-phenylcyclopropylcarbamates can be considered as promising compounds for potential medicinal applications.
- 650 _2
- $a acetylcholinesterasa $x metabolismus $7 D000110
- 650 _2
- $a butyrylcholinesterasa $x metabolismus $7 D002091
- 650 _2
- $a karbamáty $x chemická syntéza $x chemie $x farmakologie $7 D002219
- 650 _2
- $a viabilita buněk $x účinky léků $7 D002470
- 650 _2
- $a cholinesterasové inhibitory $x chemická syntéza $x chemie $x farmakologie $7 D002800
- 650 _2
- $a vztah mezi dávkou a účinkem léčiva $7 D004305
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a Jurkat buňky $7 D019169
- 650 _2
- $a molekulární struktura $7 D015394
- 650 _2
- $a vztahy mezi strukturou a aktivitou $7 D013329
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Drabina, Pavel $u a Institute of Organic Chemistry and Technology, Faculty of Chemical Technology, University of Pardubice , Pardubice , Czech Republic and.
- 700 1_
- $a Brož, Břetislav $u a Institute of Organic Chemistry and Technology, Faculty of Chemical Technology, University of Pardubice , Pardubice , Czech Republic and.
- 700 1_
- $a Štěpánková, Šárka $u b Department of Biological and Biochemical Sciences , Faculty of Chemical Technology, University of Pardubice , Pardubice , Czech Republic.
- 700 1_
- $a Vorčáková, Katarína $u b Department of Biological and Biochemical Sciences , Faculty of Chemical Technology, University of Pardubice , Pardubice , Czech Republic.
- 700 1_
- $a Královec, Karel $u b Department of Biological and Biochemical Sciences , Faculty of Chemical Technology, University of Pardubice , Pardubice , Czech Republic.
- 700 1_
- $a Havelek, Radim $u b Department of Biological and Biochemical Sciences , Faculty of Chemical Technology, University of Pardubice , Pardubice , Czech Republic.
- 700 1_
- $a Sedlák, Miloš $u a Institute of Organic Chemistry and Technology, Faculty of Chemical Technology, University of Pardubice , Pardubice , Czech Republic and.
- 773 0_
- $w MED00008009 $t Journal of enzyme inhibition and medicinal chemistry $x 1475-6374 $g Roč. 31, sup3 (2016), s. 173-179
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/27476673 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20170413 $b ABA008
- 991 __
- $a 20170502094626 $b ABA008
- 999 __
- $a ok $b bmc $g 1200075 $s 974388
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2016 $b 31 $c sup3 $d 173-179 $e 20160801 $i 1475-6374 $m Journal of enzyme inhibition and medicinal chemistry $n J Enzyme Inhib Med Chem $x MED00008009
- LZP __
- $a Pubmed-20170413